RecruitingNCT06284395

Two Schemes Response in Multiple Myeloma

Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study

Sponsor

Hospital General de Mexico

Enrollment

83 participants

Start Date

Nov 20, 2023

Study Type

OBSERVATIONAL

Conditions

Survivorship Response, Acute Phase

Summary

Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is reviewing medical records of multiple myeloma patients who were eligible for a stem cell transplant to compare outcomes between different treatment combinations given before transplant. **You may be eligible if...** - You have a diagnosis of multiple myeloma - Your medical records show you were considered healthy enough for a transplant and received a drug combination treatment **You may NOT be eligible if...** - Your medical records are incomplete - You stopped treatment or could not continue due to financial or travel difficulties - You had a severe infection (sepsis) before your treatment began Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.